Furmonertinib activity in NSCLC Harbouring EGFR L858R and ERBB2 S310F co-mutations: a case report with literature review.
Shiyue Liu, Runze Cao, Hong Li et al.
✦ AI-curated · Sources linked
Case in brief
A 61-year-old woman with advanced lung adenocarcinoma had concurrent EGFR L858R (exon 21) and ERBB2 S310F mutations identified by next-generation sequencing. She was treated with the third-generation EGFR tyrosine kinase inhibitor furmonertinib together with localized radiotherapy, and experienced a marked clinical response.
What made this case unusual
The case involved concurrent EGFR L858R and ERBB2 S310F mutations, a molecular combination whose therapeutic implications are described as poorly understood.
Diagnostic / clinical pearl
Comprehensive molecular testing can identify concurrent EGFR and ERBB2 mutations in advanced lung adenocarcinoma; this case documents a marked response to furmonertinib combined with localized radiotherapy.